iCarbonX
碳云智能
Shenzhen 'digital life' company building an AI platform that fuses multi-omics (genome, metabolome, microbiome) with lifestyle data to model individual health — an early, ambitious AI-multi-omics play whose mid-2010s hype has cooled and whose current momentum is unclear.
- Location
- Nanshan · Shenzhen
- Visit window
- From the Nanshan base · Jul 13–31
- Source status
- medium confidenceresearched
Next action
Keep the dossier ready and use the open questions if a visit window opens.
Why now: Visit window · From the Nanshan base · Jul 13–31
What they do
iCarbonX set out to build a digital-life ecosystem: collect dense, longitudinal personal biology data (genomics, metabolites, microbiome, proteomics, wearables/lifestyle) and apply machine intelligence to turn it into actionable health insight. It positioned AI as the integrating layer across heterogeneous omics and in 2017 launched a Digital Life Alliance with international data companies (SomaLogic, PatientsLikeMe, AOBiome, HealthTell).
The AI angle is multi-omics data integration / computational biology at the individual level, rather than drug discovery or bioprocess.
Why it matters
Medium fit on the AI-in-biotech pillar — more about people and data than a deal. Multi-omics + AI data integration is the same class of capability a microbial-resource-discovery platform leans on to find and characterize bioactive strains, so it is a useful benchmark for AI-compressed discovery.
Its microbiome/metabolome modeling could also inform a consumer skin/wellness evidence story at a high level. The Nanshan location minutes from the trip base makes a meeting logistically cheap.
Strong caveat: it peaked around 2016-2018 with little recent public signal, so treat it as a low-cost exploratory conversation, not a partnership pitch.
Visit objective & route
Low-cost exploratory local conversation to benchmark AI-driven multi-omics data integration and gauge whether the platform is still active and relevant to microbial-resource discovery; not a partnership pitch.
Approach route
Company contact page, a Nanshan ecosystem intro, or a BGI-network intro.
Talking points
- Benchmark AI-driven multi-omics data integration (genome/metabolome/microbiome) as a model for strain discovery and characterization.
- Explore whether microbiome/metabolome modeling could support a consumer skin/wellness evidence story.
- Understand the current status of the 'digital life' platform and any live products or partnerships.
Open questions
- Is iCarbonX still actively operating and worth a meeting in 2026? Public momentum largely stops around 2018.
- Is the multi-omics microbiome/strain modeling relevant to microbial-resource discovery, or is it general health-data modeling?
- Any current partnerships, products, or revenue since the 2017 Digital Life Alliance?
- Founder's current involvement and who handles external partnerships now.
- Which office is currently in use (confirm before travel).
Risks & unknowns
- Momentum caveat: bulk of verifiable coverage is 2015-2018; current headcount, pipeline, and whether the 'digital life' vision is still pursued are not established.
- May be a courtesy/benchmark meeting at best rather than a partnership.
- Appointment-only; verify the company is active and has a host before committing time.
Private-pack boundary